Before the pandemic, almost 1 in 4 patients were forced to discontinue treatment because of financial barriers.1 Today, cycle interruptions and economic uncertainty in some situations have caused even more financial stress. Whether your patients are resuming treatment or just starting out, our focus remains the same: to help make medications more affordable, so more patients can continue their journey to grow their family.
EMD Serono offers replacement medication to eligible patients who have had a cycle cancelled due to COVID-19. Patients may be eligible for drug replacement if cycle cancellation took place:
To initiate replacement, contact the EMD Serono Fertility Network Pharmacy who filled your patient’s prescription.
Drug Replacement Program Eligibility & Terms
Replacement Drug Program covers the following treatments:
GONAL-F® RFF* Redi-ject® (follitropin alfa injection) 300 IU, GONAL-F RFF* Redi-ject (follitropin alfa injection) 450 IU, GONAL-F RFF* Redi-ject (follitropin alfa injection) 900 IU, GONAL-F® Multi-Dose (follitropin alfa for injection) 450 IU, GONAL-F Multi-Dose (follitropin alfa for injection) 1050 IU, Cetrotide® (cetrorelix acetate injection), and Ovidrel® PreFilled syringe (choriogonadotropin alfa injection)
GONAL-F® RFF* Redi-ject (follitropin alfa injection) is indicated for:
Prior to treatment complete an evaluation of female and male partners to determine infertility diagnosis and fertility status. Primary ovarian failure and pregnancy should be excluded.
GONAL-F® Multi-Dose (follitropin alfa for injection) is indicated for:
In women:
Prior to initiation of treatment with GONAL-F Multi-Dose:
In men:
Prior to initiation of treatment with GONAL-F Multi-Dose:
Cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide® should only be prescribed by physicians who are experienced with infertility problems and their management.
Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization (IVF) and embryo transfer. Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure.
Fertility LifeLines™ is brought to you by EMD Serono to provide financial assistance and support to those looking to grow their family. It features two unique savings programs: Compassionate Care for eligible, self-pay patients and Compassionate Corps for eligible veterans. Patients can also call a live support line for insurance and savings program information and for infertility emotional support.
Compassionate Care was designed to make fertility treatments more affordable for eligible patients† without insurance or coverage for fertility medication. The program enrolled over 7,000 patients in 2020, saving them more than $11.6 million.2‡
The first program of its kind, Compassionate Care provides discounts off the self-pay price of EMD Serono fertility medications, including:
Patients can apply at FertilitySavings.com
†Subject to eligibility; restrictions apply. View program eligibility requirements and terms and conditions for more information.
‡Data based on average year-to-date savings.
Compassionate Care covers the following treatments:
GONAL-F RFF* Redi-ject (follitropin alfa injection) 300 IU, GONAL-F RFF* Redi-ject (follitropin alfa injection) 450 IU, GONAL-F RFF* Redi-ject (follitropin alfa injection) 900 IU, GONAL-F Multi-Dose (follitropin alfa for injection) 450 IU, GONAL-F Multi-Dose (follitropin alfa for injection) 1050 IU, Cetrotide® (cetrorelix acetate injection), and Ovidrel® PreFilled syringe (choriogonadotropin alfa injection)
Compassionate Care Eligibility & Terms
Compassionate Corps provides free medication to eligible, uninsured veterans injured in the line of duty or their spouses. Veterans who do not qualify for the Compassionate Corps Program are eligible for up to 50% off medications through the Compassionate Care Program.
To become a participating member, centers can contact EMD Serono directly at Fertility.Marketing@EMDSerono.com.
To help you make the most of our Fertility LifeLines™ patient savings portal, we've created the Fertility LifeLines™ Practice Resource Center—a convenient, 1-stop shop with a range of promotional and educational resources that make it easier for you to help your patients understand how to access treatment savings and information.
Summary of Contraindications Gonal-f® (follitropin alfa injection) RFF* Redi-ject® and Gonal-f® (follitropin alfa for injection) Multi-Dose are contraindicated in patients with prior hypersensitivity to r-hFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin. Please scroll for full IMPORTANT RISK INFORMATION for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and click here for full Prescribing Information for each individual product. RFF : Revised Formulation Female
Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection) Contraindications: GONAL-F® Multi-Dose is contraindicated in women and men who exhibit:
GONAL-F Multi-Dose is also contraindicated in women who exhibit:
WARNINGS Overstimulation of the Ovary During FSH Therapy: Ovarian Torsion Abnormal Ovarian Enlargement Multi-fetal Gestation and Birth Embryofetal toxicity Ectopic Pregnancy Spontaneous Abortion Ovarian Neoplasms Laboratory Tests In most instances, treatment of women with GONAL-F Multi-Dose will result only in follicular recruitment and development. In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the woman indicates that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the OHSS and multiple gestation. ADVERSE REACTIONS Men - There was one serious adverse reaction of gynecomastia requiring surgical excision of breast tissue in a 50-year-old man who received 9 months of therapy with GONAL-F Multi-Dose. Pathology report showed gynecomastia with no atypia. Adverse reactions reported in ≥ 2 patients were acne, injection site pain, gynecomastia, seborrhea, fatigue and libido decreased. Specific Populations: Pregnancy: GONAL-F Multi-Dose is not indicated in pregnant women. There is no human data that the use of gonadotropins (including GONAL-F Multi-Dose) alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations.
Lactation: There are no data on the presence of GONAL-F Multi-Dose in human milk, the effects on the breastfed infant, or the effects on milk production. Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL-F Multi-Dose.
Females and Males of Reproductive Potential: Because GONAL-F Multi-Dose is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F Multi-Dose to a woman
Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Safety and effectiveness of GONAL-F Multi-Dose in postmenopausal women have not been established and it is not indicated in this population.
Patient Counseling: Instruct women and men on the correct usage and dosing of GONAL-F Multi-Dose. Caution against changing the dosage or the schedule of administration unless instructed to do so by a healthcare provider. Prior to beginning therapy with GONAL-F Multi-Dose, inform women and men about the time commitment and monitoring procedures necessary for treatment Inform women and men that if they miss or forget to take a dose of GONAL-F Multi-Dose, they should not double the next dose and should call their healthcare provider for further dosing instructions. For more information, please see the full Prescribing Information and Instructions for Use for GONAL-F Multi-Dose Indications and Usage:
|
Important Risk Information for Cetrotide® (cetrorelix acetate for injection) Cetrotide® is contraindicated in women who are pregnant, are nursing, or have severe renal impairment. Cetrotide® is also contraindicated in women who exhibit or have known hypersensitivity to cetrorelix acetate, mannitol, extrinsic peptide hormone, GnRH or any other GnRH analogs. Treatment with Cetrotide® is not advised in women with severe allergic conditions. Cases of hypersensitivity reactions, including anaphylactoid reactions have been reported. Other adverse events reported include ovarian hyperstimulation syndrome, nausea, headache, and local injection site reactions. Multiple births and congenital abnormalities have been reported. Indication
|
Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Ovidrel® PreFilled Syringe should only be used by physicians who are experienced with infertility problems, their management and appropriate selection and monitoring of patients. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations, mannitol, or one of their other excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled intracranial lesion, abnormal uterine bleeding of an undetermined origin, an ovarian cyst or enlargement of an undetermined origin. Women who are pregnant or nursing should not use Ovidrel® PreFilled Syringe. Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications. Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported. Indication
|
Summary of Contraindications Gonal-f® (follitropin alfa injection) RFF* Redi-ject® and Gonal-f® (follitropin alfa for injection) Multi-Dose are contraindicated in patients with prior hypersensitivity to r-hFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin. Please scroll for full IMPORTANT RISK INFORMATION for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and click here for full Prescribing Information for each individual product. RFF : Revised Formulation Female
Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection) Contraindications: GONAL-F® Multi-Dose is contraindicated in women and men who exhibit:
GONAL-F Multi-Dose is also contraindicated in women who exhibit:
WARNINGS Overstimulation of the Ovary During FSH Therapy: Ovarian Torsion Abnormal Ovarian Enlargement Multi-fetal Gestation and Birth Embryofetal toxicity Ectopic Pregnancy Spontaneous Abortion Ovarian Neoplasms Laboratory Tests In most instances, treatment of women with GONAL-F Multi-Dose will result only in follicular recruitment and development. In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the woman indicates that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the OHSS and multiple gestation. ADVERSE REACTIONS Men - There was one serious adverse reaction of gynecomastia requiring surgical excision of breast tissue in a 50-year-old man who received 9 months of therapy with GONAL-F Multi-Dose. Pathology report showed gynecomastia with no atypia. Adverse reactions reported in ≥ 2 patients were acne, injection site pain, gynecomastia, seborrhea, fatigue and libido decreased. Specific Populations: Pregnancy: GONAL-F Multi-Dose is not indicated in pregnant women. There is no human data that the use of gonadotropins (including GONAL-F Multi-Dose) alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations.
Lactation: There are no data on the presence of GONAL-F Multi-Dose in human milk, the effects on the breastfed infant, or the effects on milk production. Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL-F Multi-Dose.
Females and Males of Reproductive Potential: Because GONAL-F Multi-Dose is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F Multi-Dose to a woman
Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Safety and effectiveness of GONAL-F Multi-Dose in postmenopausal women have not been established and it is not indicated in this population.
Patient Counseling: Instruct women and men on the correct usage and dosing of GONAL-F Multi-Dose. Caution against changing the dosage or the schedule of administration unless instructed to do so by a healthcare provider. Prior to beginning therapy with GONAL-F Multi-Dose, inform women and men about the time commitment and monitoring procedures necessary for treatment Inform women and men that if they miss or forget to take a dose of GONAL-F Multi-Dose, they should not double the next dose and should call their healthcare provider for further dosing instructions. For more information, please see the full Prescribing Information and Instructions for Use for GONAL-F Multi-Dose Indications and Usage:
|
Important Risk Information for Cetrotide® (cetrorelix acetate for injection) Cetrotide® is contraindicated in women who are pregnant, are nursing, or have severe renal impairment. Cetrotide® is also contraindicated in women who exhibit or have known hypersensitivity to cetrorelix acetate, mannitol, extrinsic peptide hormone, GnRH or any other GnRH analogs. Treatment with Cetrotide® is not advised in women with severe allergic conditions. Cases of hypersensitivity reactions, including anaphylactoid reactions have been reported. Other adverse events reported include ovarian hyperstimulation syndrome, nausea, headache, and local injection site reactions. Multiple births and congenital abnormalities have been reported. Indication
|
Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Ovidrel® PreFilled Syringe should only be used by physicians who are experienced with infertility problems, their management and appropriate selection and monitoring of patients. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations, mannitol, or one of their other excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled intracranial lesion, abnormal uterine bleeding of an undetermined origin, an ovarian cyst or enlargement of an undetermined origin. Women who are pregnant or nursing should not use Ovidrel® PreFilled Syringe. Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications. Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported. Indication
|